Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NKTX

Nkarta Inc

Dec 11 • 04:00PM ET

2.52

Dollar change +0.03
Percentage change 1.20	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA FATE BMRN BLUE EDIT ALLO SGMO CLLS BLRX

| Held by: VTI IWM VXF IWN VTWO IWC DFAS FESM AVSC ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.87	Insider Own	34.82%	Shs Outstand	70.57M	Perf Week	-7.35%
Market Cap	177.83M	Forward P/E	-	EPS next Y	-1.78	Insider Trans	-0.03%	Shs Float	46.00M	Perf Month	-25.66%
Income	-110.61M	PEG	-	EPS next Q	-0.40	Inst Own	68.90%	Short Float	14.45%	Perf Quarter	-54.92%
Sales	0.00M	P/S	-	EPS this Y	25.06%	Inst Trans	3.69%	Short Ratio	5.86	Perf Half Y	-60.13%
Book/sh	6.11	P/B	0.41	EPS next Y	0.84%	ROA	-23.59%	Short Interest	6.65M	Perf Year	-9.68%
Cash/sh	4.01	P/C	0.63	EPS next 5Y	-	ROE	-30.40%	52W Range	2.35 - 16.24	Perf YTD	-61.82%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-209.81%	ROI	-21.71%	52W High	-84.48%	Beta	0.83
Dividend TTM	-	Quick Ratio	12.91	Sales past 5Y	-39.65%	Gross Margin	-	52W Low	7.23%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	12.91	EPS Y/Y TTM	25.07%	Oper. Margin	-	RSI (14)	38.28	Volatility	8.72% 8.95%
Employees	150	Debt/Eq	0.20	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	16.29
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	26.29%	Payout	-	Rel Volume	4.46	Prev Close	2.49
Sales Surprise	-	EPS Surprise	-6.09%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	1.13M	Price	2.52
SMA20	-4.38%	SMA50	-22.66%	SMA200	-59.62%	Trades		Volume	4,749,006	Change	1.20%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-09-24	Initiated	Rodman & Renshaw	Buy	$14
Aug-14-24	Upgrade	Raymond James	Outperform → Strong Buy	$16
Mar-22-24	Downgrade	Raymond James	Strong Buy → Outperform	$13 → $16
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Oct-10-22	Initiated	Canaccord Genuity	Buy	$25
Jul-28-22	Initiated	Needham	Buy	$26
Jul-18-22	Initiated	SVB Leerink	Outperform	$30
Mar-11-22	Initiated	Raymond James	Outperform	$17
Mar-08-22	Initiated	H.C. Wainwright	Buy	$25
Jan-06-22	Initiated	William Blair	Outperform
Nov-18-21	Initiated	SMBC Nikko	Outperform	$50
Jul-16-21	Initiated	Oppenheimer	Outperform	$75
Aug-04-20	Initiated	Stifel	Buy	$41
Aug-04-20	Initiated	Mizuho	Buy	$34
Aug-04-20	Initiated	Evercore ISI	Outperform	$55
Aug-04-20	Initiated	Cowen	Outperform

Show Previous Ratings

Dec-05-24 06:01AM	Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2 (GlobeNewswire)
Nov-26-24 07:02AM	Nkarta to Participate in an Upcoming Investor Conference (GlobeNewswire)
Nov-22-24 06:50AM	Nkarta price target lowered to $16 from $20 at Mizuho (TipRanks)
Nov-12-24 08:02AM	Nkarta to Participate in an Upcoming Investor Conference (GlobeNewswire) -10.03%
Nov-07-24 04:02PM	Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
08:00AM	Loading…
Oct-09-24 08:00AM	Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month (Benzinga)
Sep-03-24 04:01PM	Nkarta to Participate in Upcoming Investor Conference (GlobeNewswire)
Aug-14-24 12:37PM	Why Nkarta Stock Is Soaring Today (Motley Fool)
Aug-13-24 09:03PM	Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
04:01PM	Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-24-24 06:00AM	Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus (GlobeNewswire)
Jul-16-24 06:01AM	Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President (GlobeNewswire) +13.96%
Jul-10-24 12:00PM	Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know (Zacks)
Jul-01-24 10:20AM	3 Undervalued Stocks Primed for a 2X Return (InvestorPlace)
Jun-27-24 06:00AM	Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications (GlobeNewswire)
04:01PM	Loading…
Jun-13-24 04:01PM	Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors (GlobeNewswire)
May-10-24 02:56PM	Nkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Analysis (GuruFocus.com)
May-09-24 10:57PM	NKTX Stock Earnings: Nkarta Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
May-07-24 06:30AM	Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street's Radar (InvestorPlace)
Apr-03-24 04:02PM	Nkarta to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-25-24 04:06PM	Why Nkarta Stock Just Boomeranged Following A Massive Dive On Friday (Investor's Business Daily) +17.60% -5.91%
06:30AM	Nkarta Announces Pricing of $240 Million Underwritten Offering (GlobeNewswire)
Mar-23-24 05:31AM	Nkarta Inc (NKTX) Posts Full Year 2023 Financial Results: A Focus on NKX019 and Pipeline Realignment (GuruFocus.com)
Mar-22-24 04:03PM	Why Top 1% Biotech Stock Nkarta Just Plummeted, Undercutting Its 50-Day Line (Investor's Business Daily) -31.28% +17.60%
09:18AM	Nkarta's blood cancer CAR stalls again, with falling response rate forcing it out of the race (FierceBiotech.com)
Mar-21-24 10:54PM	NKTX Stock Earnings: Nkarta Beats EPS for Q4 2023 (InvestorPlace)
04:01PM	Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-19-24 07:29AM	3 Overlooked Stocks Ready to Capture the Market by Storm (InvestorPlace) +7.19%
Feb-29-24 06:30AM	3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket (InvestorPlace) +11.13%
08:01AM	Loading…
Feb-28-24 08:01AM	Nkarta to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-20-24 04:19PM	Last Call! 7 Small-Cap Stocks Ready to Explode in Value (InvestorPlace) -7.66%
Feb-08-24 09:32AM	3 Under-the-Radar Stocks Set to Soar 300% by 2026 (InvestorPlace) +7.87%
Feb-06-24 12:50PM	3 Sleeper Stocks With Serious Potential to Make You a Millionaire (InvestorPlace) +11.95%
Feb-05-24 12:41PM	3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential (InvestorPlace) -5.59%
Feb-04-24 08:00AM	Unseen Giants: 3 Stocks Quietly Preparing for a 10X Surge (InvestorPlace)
Jan-09-24 10:25AM	Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030 (GlobeNewswire)
Dec-09-23 08:31PM	Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition (GlobeNewswire)
Dec-08-23 12:00PM	All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy (Zacks)
Nov-14-23 03:56PM	T. Rowe Price Investment Management, Inc. Reduces Stake in Nkarta Inc (GuruFocus.com) +20.42%
Nov-09-23 04:02PM	Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
11:38AM	These Biotech Stocks Could Double Your Money, According To Analysts (Benzinga)
Nov-07-23 08:02AM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire)
Oct-25-23 02:06PM	Want To Invest In Penny Stocks? Here Are Three That Analysts Think Could Deliver Over 300% Returns (Benzinga)
Oct-18-23 10:47AM	Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug (Zacks)
01:18AM	'The world increasingly needs Arm,' says KeyBanc: 4 big analyst picks (Investing.com)
Oct-17-23 08:17PM	Nkarta stock soars 112% after FDA clears cell therapy to go beyond cancer into lupus (FierceBiotech.com) +112.16%
11:47AM	Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis (PR Newswire)
07:01AM	Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis (GlobeNewswire)
Oct-16-23 04:01PM	Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures (GlobeNewswire)
Oct-02-23 03:07PM	3 Promising Biotech Stocks That Will Make Early Investors Rich (InvestorPlace) -5.76%
Aug-10-23 07:01AM	Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Aug-03-23 08:02AM	Nkarta to Participate at Upcoming Investor Conference (GlobeNewswire)
Jul-31-23 06:30PM	3 Hidden Penny Stocks That Could Turn $100 into $10,000 (InvestorPlace) +6.51%
Jul-05-23 04:02PM	Nkarta Appoints Alyssa Levin Chief Financial and Business Officer (GlobeNewswire) -6.87%
Jun-28-23 09:35AM	Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks (Zacks) -11.74%
Jun-27-23 01:02PM	Why Shares of Nkarta Are Slumping Tuesday (Motley Fool) -37.97%
07:01AM	Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia (GlobeNewswire)
Jun-26-23 04:01PM	Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program (GlobeNewswire)
Jun-15-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally Over 300% (TipRanks) +12.24%
Jun-10-23 10:47AM	Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma (GlobeNewswire)
May-11-23 04:02PM	Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
04:01PM	Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma (GlobeNewswire)
May-09-23 07:15AM	We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely (Simply Wall St.)
May-07-23 12:50PM	7 Stocks With Promising Upside Potential for 100% Returns (InvestorPlace)
Apr-17-23 05:01PM	Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting (GlobeNewswire)
Apr-12-23 09:06PM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire) +14.06%
Apr-11-23 09:46AM	3 Biotech Stocks to Watch for Potential Breakthroughs (InvestorPlace)
Mar-30-23 04:01PM	Nkarta Announces Departure of Chief Financial & Business Officer (GlobeNewswire)
Mar-16-23 04:01PM	Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-17-23 05:35AM	Nkarta, Inc. (NASDAQ:NKTX) is a favorite amongst institutional investors who own 58% (Simply Wall St.)
Feb-09-23 08:02AM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire)
Jan-09-23 04:30PM	Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer (GlobeNewswire) -7.77%
Dec-05-22 07:02AM	Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (GlobeNewswire) -5.12%
Dec-02-22 04:02PM	Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program (GlobeNewswire)
Nov-09-22 04:02PM	Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) -6.24%
Nov-07-22 08:52AM	Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting (GlobeNewswire)
Nov-02-22 08:02AM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire)
Sep-24-22 09:34AM	Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth (Simply Wall St.)
Sep-23-22 07:30AM	7 Unknown Biotech Stocks That Could Rocket in 2023 (InvestorPlace)
Aug-11-22 04:02PM	Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) +11.35%
Aug-10-22 08:42AM	Should You Buy Nkarta (NKTX) Ahead of Earnings? (Zacks)
Aug-07-22 06:15AM	Over 100% Upside: Analysts See an Appealing Entry Point in These 3 Strong Buy Stocks (TipRanks)
Jul-25-22 04:31PM	Nkarta Announces Key Senior Leadership Team Appointments (GlobeNewswire)
Jul-18-22 02:46PM	SVB Leerink Picks This Well-Positioned NK Cell-Focused Stock, Sees 117% Upside (Benzinga)
Jun-14-22 07:14AM	What Is The Ownership Structure Like For Nkarta, Inc. (NASDAQ:NKTX)? (Simply Wall St.)
Jun-07-22 09:55AM	Wall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know (Zacks)
May-31-22 07:02AM	Nkarta to Participate at Upcoming Investor Conference (GlobeNewswire) +6.49%
May-18-22 12:00PM	What Makes Nkarta, Inc. (NKTX) a New Buy Stock (Zacks) -5.29%
09:55AM	Can Nkarta, Inc. (NKTX) Climb 383% to Reach the Level Wall Street Analysts Expect? (Zacks)
May-16-22 04:02PM	Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development (GlobeNewswire)
May-12-22 04:02PM	Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) +10.57%
May-09-22 04:02PM	Positive Clinical Results Put Nkarta Stock on the Fast Track (InvestorPlace) -12.95%
May-06-22 05:30PM	MiMedx Group and Inozyme Stock See Action From Activist Investors (Barrons.com) -7.28%
May-02-22 10:45AM	Novartis Is Looking for Deals. Are These 3 Biotechs on Its List? (Motley Fool)
Apr-28-22 04:01PM	Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters Full Exercise of Option to Purchase Additional Shares (GlobeNewswire)
10:18AM	Up 131% in a Day, Is This Hot Stock a Buy? (Motley Fool)
Apr-25-22 11:19PM	Nkarta Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +140.93% -10.31%
06:04PM	Nkarta Scores Huge Gain on Cancer Treatment Results (GuruFocus.com)
05:44PM	Why this Peninsula cancer drug maker's stock soared more than 100% (American City Business Journals)

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hager Alicia J.	Chief Legal Officer	Jul 16 '24	Sale	8.00	3,396	27,168	103,819	Jul 18 04:22 PM
Trager James	Chief Scientific Officer	Jun 18 '24	Sale	5.60	456	2,554	150,959	Jun 20 05:04 PM
HASTINGS PAUL J	Chief Executive Officer	Jun 18 '24	Sale	5.60	1,770	9,912	240,737	Jun 20 05:03 PM
Shook David	Chief Medical Officer	Jun 18 '24	Sale	5.60	456	2,554	116,524	Jun 20 05:03 PM
Hager Alicia J.	Chief Legal Officer	Jun 18 '24	Sale	5.60	727	4,071	107,215	Jun 20 05:02 PM
Brandenberger Ralph	Chief Technical Officer	Jun 18 '24	Sale	5.60	229	1,282	79,743	Jun 20 05:01 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 27 '24	Buy	10.00	3,000,000	30,000,000	10,050,818	Mar 29 05:38 PM
George Simeon	Director	Mar 27 '24	Buy	10.00	2,000,000	20,000,000	1,548,341	Mar 28 04:30 PM
Brandenberger Ralph	Chief Technical Officer	Mar 01 '24	Option Exercise	3.89	6,763	26,308	88,339	Mar 05 04:26 PM
Brandenberger Ralph	Chief Technical Officer	Mar 01 '24	Sale	12.51	8,367	104,671	79,972	Mar 05 04:26 PM
Trager James	Chief Scientific Officer	Feb 12 '24	Sale	12.00	4,143	49,716	149,415	Feb 14 09:12 PM
Shook David	Chief Medical Officer	Jan 16 '24	Sale	8.74	3,552	31,044	114,980	Jan 18 04:45 PM
Trager James	Chief Scientific Officer	Jan 16 '24	Sale	8.74	4,560	39,854	153,558	Jan 18 04:43 PM
Brandenberger Ralph	Chief Technical Officer	Jan 16 '24	Sale	8.74	2,512	21,955	81,576	Jan 18 04:40 PM
HASTINGS PAUL J	Chief Executive Officer	Jan 16 '24	Sale	8.74	9,697	84,752	390,507	Jan 18 04:40 PM
Hager Alicia J.	Chief Legal Officer	Jan 16 '24	Sale	8.74	4,554	39,802	107,942	Jan 18 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NKTX

Nkarta Inc

Upgrade your FINVIZ experience